Employer Sponsored Benefits

Other Considerations

  • There are guidelines for treating obesity.
Apovian C, et al. J Clin Endocrinol Metab. 2015;100:342-362.


  • Novo Nordisk has a $225 co-pay card which will cover up to $225 each month for a prescription.
  • Adherence rates are similar to other meds.
  • Safety Factor – Concern about employees using Groupon or other off insurance markets for similar drugs from a compounding pharmacy.
  • Lifestyle is a key component.
  • Population gains about 70% of weight back when they come off the drug (still have some gain ~5%)
  • Future cost of diseases which are risk (with risk %)
    - Prevent Pre and Type 2 Diabetes (12% convert per year, add $9,600 in added expenses per year), prevent 15% of those conversations per year with 5-7% weight loss (DPP data)
    - Makes every disease we know of worse.
    - Type 2 Diabetes Remission (may use Ozempic).
    - Saw a 28% Reduction in use of other medications and:
     • Lower Blood Pressure
     • Stroke
     • Cardiac Arrest (17% reduction over 5 years)
  • Obesity as a risk factor accounts for over 47% of chronic disease costs.

Addressing Obesity through Holistic Design for Affordability and Sustainability

Obesity Treatment Pyramid

Back to Obesity Toolkit for Employers